Precision stapling for the most demanding urologic anatomy

RIOT, or Return to Intended Oncologic Treatment, is a quality metric that measures whether and how quickly a patient begins planned adjuvant or systemic therapy after surgical resection. It was first described at MD Anderson in 2014 and is now a recognized oncologic quality indicator across multiple cancer types.

RIOT (Return to Intended Oncologic Treatment) measures whether a patient starts their planned therapy after surgery, while CIOT (Completion of Intended Oncologic Therapy) measures whether they finish it. CIOT is the downstream extension of RIOT, and both correlate with disease-free and overall survival.

The evidence supports that it can, indirectly. Surgical staplers enable minimally invasive approaches, reduce operative time, and, in the case of the AEON platform, are associated with lower complication rates in pancreatic, gastric, and thoracic surgery. Each of these factors independently correlates with improved RIOT rates, and RIOT rates correlate with survival. No single variable determines oncologic outcomes, but surgical quality is an active determinant, not a passive backdrop.

Postoperative complications are the leading modifiable cause of failure to return to intended oncologic treatment. Patients who experience complications are roughly half as likely to receive their planned postoperative therapy, and complications consistently reduce RIOT rates by 50% or more.

Yes. Complication rates and surgical site infection rates double after two hours of operative time, with a dose-response relationship that increases approximately 14% for every additional 30 minutes. This makes operative time an under-recognized but modifiable driver of complications.

Six evidence-based, surgeon-controlled variables affect RIOT rates: preoperative optimization including prehabilitation and smoking cessation, complication avoidance, technology and device selection, anesthetic technique, a minimally invasive approach, and adherence to Enhanced Recovery After Surgery (ERAS) protocols.

Device selection is a direct, modifiable variable in surgical outcomes. Published data on the AEON surgical stapling platform is illustrative: in laparoscopic distal pancreatectomy, the AEON surgical stapler was associated with a postoperative pancreatic fistula rate of 20% compared with 65% for a comparator (Sheen et al., 2023). These results represent findings from individual studies and should be interpreted in clinical context, with larger prospective trials ongoing.

Eliminating the need for adjunctive hemostasis, such as suture, clip, or buttress reinforcement on staple lines, directly reduces operative time and surgical complexity. Because operative time and complications are linked, more consistent staple-line hemostasis can contribute to a lower overall complication burden.

Yes. Substantial evidence across gastrointestinal, thoracic, and gynecologic oncology shows that minimally invasive surgery improves RIOT rates, consistent with shorter recovery times and lower complication rates. MIS is also associated with reduced perioperative immunosuppression, which may carry oncologic implications beyond recovery alone.

ERAS, or Enhanced Recovery After Surgery, refers to multimodal, specialty-specific protocols applied from prehabilitation through discharge. These protocols consistently reduce length of stay, complication rates, and total cost of care, which supports a patient’s ability to return to intended oncologic treatment.